Collegium Pharmaceutical stock reports ADHD growth in Q2
Collegium Pharmaceutical reported a 6% year-over-year increase in Q2 2026 net product revenue, reaching USD 199.9 million, primarily driven by its ADHD portfolio. Jornay PM revenue surged by 41% to USD 46.1 million, and Azstarys contributed USD 12.9 million in its first partial quarter after acquisition. Despite a strong outlook for ADHD drugs, the pain portfolio's Nucynta revenue declined, leading to an adjusted EBITDA forecast that is essentially flat compared to 2025.
Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript
Collegium Pharmaceutical reported strong Q2 2026 results, driven by significant growth in its ADHD business, particularly with Jornay PM and the newly acquired Azstarys. While the pain portfolio saw mixed results due to lower net pricing for Nucynta generics, the company updated its 2026 guidance with increased expectations for Azstarys and maintained its long-term strategic focus on CNS and rare diseases. Collegium is relocating its headquarters to Boston in 2027 and remains committed to disciplined capital deployment, including potential future acquisitions.
Oppenheimer sets USD 50.00 target for Collegium Pharmaceutical stock
Oppenheimer has initiated coverage on Collegium Pharmaceutical (COLL) with an Outperform rating and a USD 50.00 price target. The company's second-quarter revenue reached USD 199.88 million, up 6.30 percent, with ADHD portfolio growth offsetting pressure on older pain products. Collegium Pharmaceutical was trading at EUR 19.65 at Lang & Schwarz, up 1.03 percent.
Form 144 COLLEGIUM PHARMACEUTICAL For: 1 October By Investing.com
This article from Investing.com announces a Form 144 filing for COLLEGIUM PHARMACEUTICAL on October 1st. Form 144 filings indicate an insider's intent to sell restricted stock, but the article provides no further details regarding the transaction itself. It appears to be an automated notification of the filing.
Form 144 COLLEGIUM PHARMACEUTICAL For: 1 October By Investing.com
This article reports on the filing of Form 144 by COLLEGIUM PHARMACEUTICAL for October 1st. Form 144 is filed with the SEC when an insider intends to sell restricted or controlled securities. The article does not provide further details regarding the nature of the filing.
Form 144 COLLEGIUM PHARMACEUTICAL For: 1 October By Investing.com
This article announces the filing of Form 144 for COLLEGIUM PHARMACEUTICAL on October 1, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The brief post from Investing.com provides no further details beyond this announcement.
Former officer Scott Dreyer proposes selling 27,419 Collegium Pharmaceutical (COLL) shares.
Former Collegium Pharmaceutical (COLL) officer Scott Dreyer has proposed selling 27,419 common shares with an aggregate market value of $603,320.70. The proposed sale, dated September 30, 2026, is being conducted through Fidelity Brokerage Services LLC and is related to restricted stock vesting for compensation. The Form 144 filing indicates that the securities were acquired on September 23, 2026, through restricted stock vesting.
Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts
Argus has issued a research report on Collegium Pharmaceutical Inc. (COLL), raising its target price to $22.00. The report, published on September 23, 2026, indicates a current stock price of $22.53. Collegium Pharmaceutical Inc. is identified as a specialty pharmaceutical company.
Collegium Pharmaceutical stock falls 1.45 percent near yearly low
Collegium Pharmaceutical stock fell 1.45% to USD 22.45 on September 23, 2026, placing it 3.7% above its 52-week low. Despite this, the company reported a 6.3% increase in Q2 2026 revenue, reaching USD 199.9 million, and adjusted EPS of USD 1.92, exceeding analyst estimates. Oppenheimer initiated coverage with an Outperform rating and a price target of USD 50.00, suggesting a significant upside.
Oppenheimer initiates Collegium Pharmaceutical stock at Outperform By Investing.com
Oppenheimer has initiated coverage on Collegium Pharmaceutical Inc. (NASDAQ:COLL) with an Outperform rating and a price target of $50.00, citing the stock's undervaluation and the company's transition to a scalable CNS growth platform. The firm highlights Collegium's patent-protected ADHD assets, Jornay PM and Azstarys, as key growth drivers and notes the pain portfolio's strong cash flow generation supporting deleveraging and share repurchases. Despite a slight revenue miss, Collegium recently beat EPS estimates and raised its full-year revenue outlook, further reinforcing the positive outlook.
Oppenheimer initiates Collegium Pharmaceutical stock at Outperform
Oppenheimer has initiated coverage on Collegium Pharmaceutical Inc. (NASDAQ: COLL) with an Outperform rating and a $50 price target, citing the stock's undervaluation and the company's transition to a scalable CNS growth platform. The firm highlights the potential of Collegium's ADHD assets, Jornay PM and Azstarys, to drive growth, supported by robust cash flow from its pain portfolio. Recent Q2 2026 earnings showed an adjusted EPS beat despite a slight revenue miss, with the company raising its full-year revenue outlook and continuing share repurchases.
Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target
Oppenheimer has initiated coverage on Collegium Pharmaceutical (COLL) with an Outperform rating and a $50 price target. This new rating is above the current average analyst rating of "buy" and mean price target of $48.86 for the company. The full details of this report require a premium subscription.
Collegium Pharmaceutical stock holds as market data show no catalyst
This article reports on Collegium Pharmaceutical (COLL) stock data, noting that available market pages for September 23, 2026, do not substantiate a quotation for the stock. While the company's identity and Nasdaq listing remain central, no specific price, market capitalization, or trading volume figures for COLL are provided. The report clarifies that market data for other Nasdaq-listed companies, like PC Connection, should not be mistakenly applied to Collegium Pharmaceutical.
(COLL) Movement as an Input in Quant Signal Sets
The article provides an AI-generated quantitative analysis for Collegium Pharmaceutical Inc. (NASDAQ: COLL), indicating weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, identifying support and resistance levels. The report highlights elevated downside risk due to the absence of long-term support signals.
Two Collegium presentations will be streamed live Sept. 15-16
Collegium Pharmaceutical (COLL) will participate in two upcoming investor conferences: the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. Management will hold a fireside chat and give a presentation, respectively, at these events in New York. Live webcasts and 90-day replays will be available on the company's website.
Israel A. Englander reports new Collegium (NASDAQ: COLL) stake
Israel A. Englander, along with Millennium Management LLC and Millennium Group Management LLC, has reported a new 5.6% beneficial stake in Collegium Pharmaceutical, Inc. (NASDAQ: COLL), owning 1,820,330 shares. Integrated Core Strategies (US) LLC also reported a 5.4% stake, holding 1,769,122 shares. The Schedule 13G filing indicates shared voting and dispositive power among these entities, with no party claiming sole voting power over the shares.
ETFs Investing in Collegium Pharmaceutical, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Collegium Pharmaceutical, Inc. The ETFs are sorted by market value and provide details such as their weight of Collegium Pharmaceutical in their portfolio, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year NAV total return. The information aims to help investors identify accessible investment opportunities with lower risk through ETFs.
Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Cuts Target Price to $48
Barclays has reiterated its Buy rating on Collegium Pharmaceutical (COLL.US) but has reduced its price target for the company's stock to $48. This indicates a continued positive outlook on the stock's performance, albeit with a slightly adjusted valuation expectation.
Collegium Pharmaceutical Number of Employees 2026 | Employee Count & Headcount Data
Collegium Pharmaceutical (NASDAQ: COLL) has approximately 438 employees worldwide as of March 2026, marking a 14.1% growth from 2023. While overall growth is positive, the company's headcount saw a 1.2% year-over-year decline in 2026. The company is actively hiring, with job postings up 73% in 2026, but employee sentiment is reported as negative and declining.
Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock
Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 5.03% in COLLEGIUM PHARMACEUTICAL, INC (COLL) common stock, totaling 1,632,780.71 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are held in accounts for advisory clients who retain the rights to dividends and sale proceeds. This disclosure was made via a SCHEDULE 13G filing with the SEC.
COLLEGIUM PHARMACEUTICAL INC : NEEDHAM CUTS TARGET PRICE TO $46 FROM $56
Needham has revised its target price for Collegium Pharmaceutical Inc (NASDAQ: COLL) downwards from $56 to $46. This article, published on August 7th, highlights the analyst's updated outlook on the pharmaceutical company.
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced a $50 million Accelerated Share Repurchase (ASR) program with Jefferies LLC, as part of a larger $150 million share repurchase authorization. The company believes its current valuation does not fully reflect its strong financial position, growing ADHD portfolio, and future prospects, making the share repurchase a compelling opportunity to create long-term shareholder value. The ASR is expected to be completed by the fourth quarter of 2026.
Collegium Pharmaceutical to repurchase $50 million in stock By Investing.com
Collegium Pharmaceutical announced an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock. This is part of a larger $150 million share repurchase program authorized by the company's Board of Directors in July 2025, leaving $100 million remaining after this transaction. The final number of shares will be based on volume-weighted average prices and is expected to settle no later than the fourth quarter of 2026.
Collegium Pharmaceutical to repurchase $50 million in stock
Collegium Pharmaceutical announced an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock. This action is part of a larger $150 million share repurchase program authorized in July 2025, leaving $100 million remaining after this transaction. The company will initially receive 1,556,420 shares, with the final number determined by volume-weighted average prices during the ASR term, and attributes this move to its strong financial position and robust cash generation.
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced a $50 million Accelerated Share Repurchase (ASR) program with Jefferies LLC, part of a larger $150 million authorization. The company believes its current valuation undervalues its business strength and future prospects, especially given its growing ADHD portfolio and robust cash generation. This move is intended to create long-term shareholder value and is expected to be completed by the fourth quarter of 2026.
Collegium Pharmaceutical to repurchase $50 million in stock By Investing.com
Collegium Pharmaceutical has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock, part of a larger $150 million share repurchase program. The company will receive an initial delivery of 1,556,420 shares, representing about 80% of the total expected repurchase, with the final settlement anticipated by the fourth quarter of 2026. This move highlights Collegium's strong financial position and disciplined capital allocation strategy.
Collegium Pharmaceutical Launches $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. has initiated a $50 million accelerated share repurchase program with Jefferies LLC, utilizing part of its $150 million authorization. This move aims to return cash to shareholders while the company continues to invest in its drug portfolio and reduce debt. The company believes its current valuation does not fully reflect the growth potential of its ADHD portfolio or the durability of its pain business.
Collegium gains on accelerated share buybacks (COLL:NASDAQ)
Collegium Pharmaceutical (COLL) saw its stock rise in premarket trading after announcing an accelerated share repurchase agreement with Jefferies (JEF) to buy back $50 million of its company stock. This accelerated buyback is part of a larger $150 million share repurchase program authorized by Collegium.
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced a $50 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC, part of its larger $150 million share repurchase program authorized in July 2025. This move reflects the company's strong financial position and confidence in its ADHD portfolio, aiming to enhance long-term shareholder value. The ASR is expected to be completed by the fourth quarter of 2026, with 1,556,420 shares initially delivered based on the closing stock price on August 12, 2026.
Collegium Pharmaceutical launches $50M accelerated share repurchase under $150M buyback program
Collegium Pharmaceutical has initiated a $50 million accelerated share repurchase (ASR) program with Jefferies, receiving an initial 1,556,420 shares. This ASR is part of a larger $150 million board-authorized buyback program, with the final share count to be determined by the volume-weighted average price (VWAP) during the ASR term, expected to settle by Q4 2026. The company had approximately 32.5 million shares outstanding as of June 30, 2026.
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc. announced an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This ASR is part of a larger $150 million share repurchase program, leaving $100 million remaining after this transaction. The company believes its current valuation does not fully reflect its strong financial position, rapidly growing ADHD portfolio, and robust cash generation, making the share repurchase a compelling opportunity to create long-term shareholder value.
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call
Collegium Pharmaceutical's Q2 earnings showed sales growth driven by its ADHD business, with Jornay PM revenue up 41% year-over-year, but overall revenue missed Wall Street estimates due to pricing pressure on the NUCYNTA pain franchise. Despite this, the company raised its full-year revenue guidance. Analysts focused on generic pricing stabilization, Azstarys' demand drivers, dual ADHD product promotion, and future capital deployment for CNS and rare disease assets.
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
Collegium Pharmaceutical (COLL) missed Q2 CY2026 revenue expectations but beat non-GAAP profit estimates, with sales increasing 6.3% year-on-year. The company's revenue guidance for the full year was lifted, primarily due to strong performance in its ADHD business, particularly Jornay PM and the integration of Azstarys. However, the pain management segment, especially the NUCYNTA franchise, faced headwinds from pricing pressure, which is expected to continue to impact overall performance despite stabilization.
Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops
Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2026 sales of $199.9 million, missing analyst estimates, though revenue rose 6.3% year-on-year. The company's full-year revenue guidance was below analyst expectations, but its non-GAAP profit per share exceeded consensus estimates. The stock traded down 6.6% after the report, closing at $33.37.
Collegium Pharmaceutical, Inc. $COLL Shares Acquired by Sei Investments Co.
Sei Investments Co. significantly increased its stake in Collegium Pharmaceutical, Inc. ($COLL) by 191.6% in the first quarter, acquiring 85,830 additional shares, bringing its total holding to 130,620 shares valued at approximately $4.32 million. Other institutional investors also adjusted their positions, with Jennison Associates LLC initiating a new position. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $57.50, following recent earnings that surpassed estimates.
Collegium Pharmaceutical, Inc. Revenue Breakdown – NASDAQ:COLL
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) generated $780.57 million USD in revenue last year, primarily from its Pharmaceutical segment. This marks an increase from the previous year's $631.45 million USD, with the United States being the sole contributor to this revenue. The financial data highlights the company's strong performance in its core pharmaceutical business within the US market.
Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze
Collegium Pharmaceutical (COLL) experienced a 1.2% stock increase after Q2 earnings, despite swinging from a profit to a net loss of US$15.1 million. While revenue grew to US$199.9 million, driven by its ADHD portfolio, the company faced a significant margin squeeze due to acquisition costs and authorized generics in pain treatments. This situation raises concerns about the long-term earnings path, despite the company's efforts to diversify beyond its pain-focused origins.
Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze
Collegium Pharmaceutical (COLL) saw its stock inch up 1.2% despite swinging from a Q1 profit to a Q2 loss, primarily due to a deepening margin squeeze. While revenue grew to US$199.9m, driven by its ADHD portfolio, profitability was pressured by acquisition costs and authorized generics in pain treatments. The article discusses the bull case focused on ADHD growth and the bear case highlighting margin strain and declining pain brand revenues.
Collegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at Wall Street Zen
Wall Street Zen has downgraded Collegium Pharmaceutical (NASDAQ:COLL) from "Buy" to "Hold," leading to mixed analyst views but a consensus "Moderate Buy" rating with an average price target of $52.60. Despite exceeding Q2 earnings expectations with strong ADHD portfolio growth, the company lowered its full-year product revenue and adjusted EBITDA guidance due to weaker pricing and Nucynta performance, resulting in a GAAP net loss. Other analysts like Zacks, Needham, and Piper Sandler also adjusted their ratings or price targets, reflecting ongoing caution despite some positive growth areas.
Collegium Pharmaceutical (NASDAQ:COLL) Releases Earnings Results, Beats Estimates By $0.20 EPS
Collegium Pharmaceutical (NASDAQ:COLL) announced quarterly earnings that surpassed analyst estimates, reporting $1.92 EPS against a consensus of $1.72, and revenue of $199.88 million. The company experienced strong growth in its ADHD portfolio, particularly with JORNAY PM and the recent AZSTARYS acquisition, but faced declines in its pain portfolio products, leading to a reduction in full-year product-revenue and adjusted EBITDA guidance. Despite the mixed results and a GAAP net loss, the ADHD segment's performance and strategic acquisitions highlight the company's efforts to diversify its revenue streams.
Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return
Collegium Pharmaceutical (COLL) stock has seen a 59.8% gain over five years, but a recent pullback and strong valuation checks suggest it may be undervalued. The company trades at a P/E of 12.6x, below the industry average, indicating a discount. Its future valuation depends on sustaining prescription demand and protecting margins to maintain earnings reliability.
Collegium Pharmaceutical, Inc. Stock 12‑Month Price Target Cut to $51.2, Implies 43% Upside
Collegium Pharmaceutical, Inc. (COLL) has seen its average 12-month price target reduced from $53.6 to $51.2 by 5 analysts, with individual forecasts ranging from $43 to $60. Despite this cut, the updated target still implies a significant 43% potential upside from its August 5 closing price. The consensus rating for COLL remains a "Buy," with 4 analysts recommending Buy and 1 recommending Hold.
Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return
Collegium Pharmaceutical (COLL) stock has seen a nearly 60% return over the past five years but may still be trading at a discount. Despite recent weakness, the company screens as undervalued in most measures, with its current P/E ratio of 12.6x being below the industry average. The market's lower valuation may reflect concerns about risks or business mix, and the stock's future performance hinges on its ability to sustain prescription demand and protect margins.
Collegium Pharmaceutical, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:COLL) 2026-08-07
Collegium Pharmaceutical, Inc. (COLL) released its Q2 2026 earnings call presentation. The company reported an EPS of $1.92, beating estimates by $0.16, and revenue of $199.88M, which missed estimates by $1.07M but represented a 6.32% year-over-year increase. This presentation provides details on their financial performance for the quarter.
Collegium Pharmaceutical Inc (COLL) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Collegium Pharmaceutical Inc (COLL), detailing its current price momentum score, support and resistance levels, and indicator readings. It also covers moving average data and offers a technical summary, suggesting the stock is currently suitable for range-bound swing trading with a neutral signal based on technical indicators.
Collegium Pharmaceutical Releases Q2 2026 Financial Results
Collegium Pharmaceutical Inc. reported mixed Q2 2026 financial results, with adjusted earnings of $1.92 per share exceeding expectations, but revenue of $199.9M slightly missing estimates. The company's product, JORNAY PM, showed significant revenue growth of 41.0%, contributing to the positive outlook. Management issued full-year revenue guidance between $825.0M and $855.0M, and Wall Street maintains a positive sentiment with predominantly buy ratings.
Collegium Pharmaceutical falls 13% on weak revenue guidance By Investing.com
Collegium Pharmaceutical Inc. (NASDAQ:COLL) saw its shares tumble 13.5% after reporting second-quarter results that missed revenue expectations and issuing weaker-than-expected full-year guidance. While adjusted earnings per share beat estimates, revenue of $199.9 million fell short of analyst forecasts. The company updated its full-year 2026 revenue guidance to $825 million-$855 million, significantly below the previous outlook and analyst consensus, primarily due to lower-than-expected revenue from authorized generic versions of Nucynta.
Collegium Pharmaceutical falls 13% on weak revenue guidance
Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares dropped 13.5% after reporting Q2 results that missed revenue expectations and issuing weaker-than-expected full-year guidance. Although adjusted EPS beat estimates, revenue fell short, and the company lowered its 2026 revenue and adjusted EBITDA forecasts. The decline was primarily attributed to lower-than-expected revenue from generic versions of Nucynta.
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium Pharmaceutical, Inc. reported strong Q2 2026 financial results, with net revenues up 6% year-over-year to $199.9 million, driven by a 41% increase in JORNAY PM revenue and the successful acquisition and initial sales of AZSTARYS. The company updated its full-year 2026 financial guidance, adjusting product revenues and Adjusted EBITDA due to lower-than-expected Nucynta AG revenue, while reaffirming and raising guidance for its ADHD portfolio. Collegium also highlighted strategic priorities including growth in its ADHD business, maximizing its pain portfolio, and capital deployment to enhance shareholder value.
Collegium Pharmaceutical (COLL): Principal Global Investors discloses 5% equity stake
Principal Global Investors has filed a Schedule 13G, reporting a passive 5% equity stake in Collegium Pharmaceutical, Inc. The firm beneficially owns 1,632,360 shares of common stock with shared voting and dispositive power. Both companies' principal offices are noted, with Collegium Pharmaceutical in Stoughton, Massachusetts, and Principal Global Investors in Des Moines, Iowa.
